Yeast two-hybrid methods and their applications in drug discovery

Trends in Pharmacological Sciences

Volumn 33, Issue 2, 2012, Pages 109-118

  Hamdi, Amel ^a   Colas, Pierre ^a  

^a STATION BIOLOGIQUE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; ANTINEOPLASTIC AGENT; CALCIUM CHANNEL N TYPE; FK 506 BINDING PROTEIN; MAX PROTEIN; MYC PROTEIN; NAVITOCLAX; NUTLIN 3; POTASSIUM CHANNEL KV1.1; RAF PROTEIN; RAS PROTEIN; ROSCOVITINE; SHAL POTASSIUM CHANNEL; TRANSCRIPTION FACTOR NRF2; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ANTINEOPLASTIC ACTIVITY; DRUG RESEARCH; DRUG TARGETING; HEMATOLOGIC MALIGNANCY; HIGH THROUGHPUT SCREENING; HUMAN; LUMINESCENCE; LUNG SMALL CELL CANCER; METHODOLOGY; MOLECULAR RECOGNITION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN INTERACTION; RETINOBLASTOMA; REVIEW; TWO HYBRID SYSTEM;

ANIMALS; DRUG DISCOVERY; HUMANS; TWO-HYBRID SYSTEM TECHNIQUES;

EID: 84856511126     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2011.10.008     Document Type: Review

References (93)

1. S. Fields, and O. Song A novel genetic system to detect protein-protein interactions Nature 340 1989 245 246 (Pubitemid 19171591)
2. S. Fields Interactive learning: lessons from two hybrids over two decades Proteomics 9 2009 5209 5213
3. V. Ratushny, and E. Golemis Resolving the network of cell signaling pathways using the evolving yeast two-hybrid system Biotechniques 44 2008 655 662 (Pubitemid 351656285)
4. B. Suter Two-hybrid technologies in proteomics research Curr. Opin. Biotechnol. 19 2008 316 323
5. C.F. Cheok Translating p53 into the clinic Nat. Rev. Clin. Oncol. 8 2011 25 37
6. N. Saxena RAS: target for cancer therapy Cancer Invest. 26 2008 948 955
7. G. Maurer Raf kinases in cancer - roles and therapeutic opportunities Oncogene 30 2011 3477 3488
8. J.R. Parrish Yeast two-hybrid contributions to interactome mapping Curr. Opin. Biotechnol. 17 2006 387 393 (Pubitemid 44163455)
9. M. Koegl, and P. Uetz Improving yeast two-hybrid screening systems Brief Funct. Genomic Proteomic 6 2007 302 312 (Pubitemid 351890477)
10. U. Stelzl A human protein-protein interaction network: a resource for annotating the proteome Cell 122 2005 957 968 (Pubitemid 41345212)
11. J.F. Rual Towards a proteome-scale map of the human protein-protein interaction network Nature 437 2005 1173 1178
12. J. Lim A protein-protein interaction network for human inherited ataxias and disorders of Purkinje cell degeneration Cell 125 2006 801 814 (Pubitemid 43732348)
13. M. Albers Automated yeast two-hybrid screening for nuclear receptor-interacting proteins Mol. Cell. Proteomics 4 2005 205 213 (Pubitemid 40361182)
14. A. von Brunn Analysis of intraviral protein-protein interactions of the SARS coronavirus ORFeome PLoS ONE 2 2007 e459
15. M.A. Calderwood Epstein-Barr virus and virus-human protein interaction maps Proc. Natl. Acad. Sci. U.S.A. 104 2007 7606 7611 (Pubitemid 47185953)
16. T. Stellberger Improving the yeast two-hybrid system with permutated fusions proteins: the Varicella Zoster virus interactome Proteome Sci. 8 2010 8
17. J.R. Parrish A proteome-wide protein interaction map for Campylobacter jejuni Genome Biol. 8 2007 R130
18. B. Titz The binary protein interactome of Treponema pallidum - the syphilis spirochete PLoS ONE 3 2008 e2292
19. S. Lacomble A protein-protein interaction map of the Trypanosoma brucei paraflagellar rod PLoS ONE 4 2009 e7685
20. B. de Chassey Hepatitis C virus infection protein network Mol. Syst. Biol. 4 2008 230
21. S.D. Shapira A physical and regulatory map of host-influenza interactions reveals pathways in H1N1 infection Cell 139 2009 1255 1267
22. S. Khadka A physical interaction network of dengue virus and human proteins Mol. Cell. Proteomics 2011 10.1074/mcp.M111.012187
23. S. Margeridon-Thermet, and R.W. Shafer Comparison of the mechanisms of drug resistance among HIV, Hepatitis B, and Hepatitis C Viruses 2 2010 2696 2739
24. G.L. French The continuing crisis in antibiotic resistance Int. J. Antimicrob. Agents 36 Suppl. 3 2010 S3 S7
25. A.C. Gavin Recent advances in charting protein-protein interaction: mass spectrometry-based approaches Curr. Opin. Biotechnol. 22 2011 42 49
26. M. Vidal Interactome networks and human disease Cell 144 2011 986 998
27. P.F. Jonsson, and P.A. Bates Global topological features of cancer proteins in the human interactome Bioinformatics 22 2006 2291 2297 (Pubitemid 44390886)
28. Q. Zhong Edgetic perturbation models of human inherited disorders Mol. Syst. Biol. 5 2009 321
29. A. Reymond, and R. Brent p16 proteins from melanoma-prone families are deficient in binding to Cdk4 Oncogene 11 1995 1173 1178
30. R. Hooft van Huijsduijnen, and C. Rommel Decompartmentalizing target validation-thinking outside the pipeline boxes J. Mol. Med. (Berl.) 84 2006 802 813 (Pubitemid 44478864)
31. L. Hutchinson, and R. Kirk High drug attrition rates - where are we going wrong? Nat. Rev. Clin. Oncol. 8 2011 189 190
32. Z.A. Knight, and K.M. Shokat Chemical genetics: where genetics and pharmacology meet Cell 128 2007 425 430 (Pubitemid 46198904)
33. C.J. O'Connor Chemical genetics Chem. Soc. Rev. 40 2011 4332 4345
34. A. Gaulton ChEMBL: a large-scale bioactivity database for drug discovery Nucleic Acids Res. 2011 10.1093/nar/gkr777
35. P. Colas The eleven-year switch of peptide aptamers J. Biol. 7 2008 2
36. C. Borghouts Peptide aptamer libraries Comb. Chem. High Throughput Screen. 11 2008 135 145 (Pubitemid 351347218)
37. A. Appert Targeting LMO2 with a peptide aptamer establishes a necessary function in overt T-cell neoplasia Cancer Res. 69 2009 4784 4790
38. A.L. Rerole Peptides and aptamers targeting HSP70: a novel approach for anticancer chemotherapy Cancer Res. 71 2011 484 495
39. B. Gibert Inhibition of heat shock protein 27 (HspB1) tumorigenic functions by peptide aptamers Oncogene 30 2011 3672 3681
40. N. Abed A comparative analysis of perturbations caused by a gene knock-out, a dominant negative allele, and a set of peptide aptamers Mol. Cell. Proteomics 6 2007 2110 2121
41. P. Pamonsinlapatham A RasGAP SH3 peptide aptamer inhibits RasGAP-Aurora interaction and induces caspase-independent tumor cell death PLoS ONE 3 2008 e2902
42. C.R. Geyer 'Mutagenesis' by peptide aptamers identifies genetic network members and pathway connections Proc. Natl. Acad. Sci. U.S.A. 96 1999 8567 8572 (Pubitemid 29354832)
43. B. de Chassey An antiproliferative genetic screening identifies a peptide aptamer that targets calcineurin and up-regulates its activity Mol. Cell. Proteomics 6 2007 451 459
44. A.S. Lo Intracellular antibodies (intrabodies) and their therapeutic potential Handb. Exp. Pharmacol. 2008 343 373
45. O. Vielemeyer Characterization of single chain antibody targets through yeast two hybrid BMC Biotechnol. 10 2010 59
46. I. Crnkovic-Mertens Isolation of peptides blocking the function of anti-apoptotic Livin protein Cell. Mol. Life Sci. 67 2010 1895 1905
47. J.A. Wells, and C.L. McClendon Reaching for high-hanging fruit in drug discovery at protein-protein interfaces Nature 450 2007 1001 1009 (Pubitemid 350273630)
48. T. Berg Small-molecule inhibitors of protein-protein interactions Curr. Opin. Drug Discov. Dev. 11 2008 666 674
49. C.M. Rudin A phase IIa study of ABT-263 in patients with relapsed small-cell lung cancer (SCLC) J. Clin. Oncol. 28 2010 7046
50. P. Secchiero Recent advances in the therapeutic perspectives of Nutlin-3 Curr. Pharm. Des. 17 2011 569 577
51. P. Colas High-throughput screening assays to discover small-molecule inhibitors of protein interactions Curr. Drug Discov. Technol. 5 2008 190 199
52. J. Kato-Stankiewicz Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells Proc. Natl. Acad. Sci. U.S.A. 99 2002 14398 14403 (Pubitemid 35257683)
53. X. Yin Low molecular weight inhibitors of Myc-Max interaction and function Oncogene 22 2003 6151 6159 (Pubitemid 37281644)
54. B.W. Nieuwenhuijsen A dual luciferase multiplexed high-throughput screening platform for protein-protein interactions J. Biomol. Screen. 8 2003 676 684
55. C. Bardou Peptide aptamers for small molecule drug discovery Methods Mol. Biol. 535 2009 373 388
56. K. Young Identification of a calcium channel modulator using a high throughput yeast two-hybrid screen Nat. Biotechnol. 16 1998 946 950 (Pubitemid 28483623)
57. Q. Lu Disruption of Kv1.1 N-type inactivation by novel small molecule inhibitors (disinactivators) Bioorg. Med. Chem. 16 2008 3067 3075 (Pubitemid 351418198)
58. J. Huang, and S.L. Schreiber A yeast genetic system for selecting small molecule inhibitors of protein-protein interactions in nanodroplets Proc. Natl. Acad. Sci. U.S.A. 94 1997 13396 13401 (Pubitemid 28009592)
59. T. Gunde Quenching accumulation of toxic galactose-1-phosphate as a system to select disruption of protein-protein interactions in vivo Biotechniques 37 2004 844 852 (Pubitemid 39488465)
60. P.B. Joshi Identification of protein interaction antagonists using the repressed transactivator two-hybrid system Biotechniques 42 2007 635 644 (Pubitemid 46932738)
61. A.V. deCarvalho A novel natural product compound enhances cAMP-regulated chloride conductance of cells expressing CFTRΔF508 Mol. Med. 8 2002 75 87
62. L. Li The natural product Aristolactam AIIIa as a new ligand targeting the polo-box domain of polo-like kinase 1 potently inhibits cancer cell proliferation Acta Pharmacol. Sin. 30 2009 1443 1453
63. R. Brent, and R.L. Finley Jr. Understanding gene and allele function with two-hybrid methods Annu. Rev. Genet. 31 1997 663 704 (Pubitemid 28023723)
64. C. Corbel First BRET-based screening assay performed in budding yeast leads to the discovery of CDK5/p25 interaction inhibitors Biotechnol. J. 6 2011 860 870
65. E.J. Licitra, and J.O. Liu A three-hybrid system for detecting small ligand-protein receptor interactions Proc. Natl. Acad. Sci. U.S.A. 93 1996 12817 12821 (Pubitemid 26382726)
66. H. Lin Dexamethasone-methotrexate: an efficient chemical inducer of protein dimerization in vivo J. Am. Chem. Soc. 122 2000 4247 4248 (Pubitemid 30304874)
67. F. Becker A three-hybrid approach to scanning the proteome for targets of small molecule kinase inhibitors Chem. Biol. 11 2004 211 223 (Pubitemid 38300291)
68. L.A. Fernandez, and S. Muyldermans Recent developments in engineering and delivery of protein and antibody therapeutics Curr. Opin. Biotechnol. 22 2011 1 4
69. C. Borghouts Monomeric recombinant peptide aptamers are required for efficient intracellular uptake and target inhibition Mol. Cancer Res. 6 2008 267 281 (Pubitemid 351342415)
70. P. Colas Targeted modification and transportation of cellular proteins Proc. Natl. Acad. Sci. U.S.A. 97 2000 13720 13725
71. P. Colas Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2 Nature 380 1996 548 550 (Pubitemid 26110646)
72. E. Mazuc A novel druglike spleen tyrosine kinase binder prevents anaphylactic shock when administered orally J. Allergy Clin. Immunol. 122 2008 188 194
73. L. Berrade Protein microarrays: novel developments and applications Pharm. Res. 28 2011 1480 1499
74. S. Laurenson Development of peptide aptamer microarrays for detection of HPV16 oncoproteins in cell extracts Anal. Biochem. 410 2011 161 170
75. P. Estrela Label-free sub-picomolar protein detection with field-effect transistors Anal. Chem. 82 2010 3531 3536
76. A.S. Schwartz Cost-effective strategies for completing the interactome Nat. Methods 6 2009 55 61
77. H. Yu Next-generation sequencing to generate interactome datasets Nat. Methods 8 2011 478 480
78. A. Pujol Unveiling the role of network and systems biology in drug discovery Trends Pharmacol. Sci. 31 2010 115 123
79. J.C. Fuller Predicting druggable binding sites at the protein-protein interface Drug Discov. Today 14 2009 155 161
80. N. Sugaya, and K. Ikeda Assessing the druggability of protein-protein interactions by a supervised machine-learning method BMC Bioinform. 10 2009 263
81. R. Bourgeas Atomic analysis of protein-protein interfaces with known inhibitors: the 2P2I database PLoS ONE 5 2010 e9598
82. O. Sperandio Rationalizing the chemical space of protein-protein interaction inhibitors Drug Discov. Today 15 2010 220 229
83. X. Morelli Chemical and structural lessons from recent successes in protein-protein interaction inhibition (2P2I) Curr. Opin. Chem. Biol. 15 2011 475 481
84. R. Brent, and M. Ptashne A eukaryotic transcriptional activator bearing the DNA specificity of a prokaryotic repressor Cell 43 1985 729 736
85. C.T. Chien The two-hybrid system: a method to identify and clone genes for proteins that interact with a protein of interest Proc. Natl. Acad. Sci. U.S.A. 88 1991 9578 9582
86. I. Lemmens Strategies towards high-quality binary protein interactome maps J. Proteomics 73 2010 1415 1420
87. H. Yu High-quality binary protein interaction map of the yeast interactome network Science 322 2008 104 110
88. P. Braun An experimentally derived confidence score for binary protein-protein interactions Nat. Methods 6 2009 91 97
89. J. Yu, and R.L. Finley Jr. Combining multiple positive training sets to generate confidence scores for protein-protein interactions Bioinformatics 25 2009 105 111
90. J.P. Overington How many drug targets are there? Nat. Rev. Drug Discov. 5 2006 993 996 (Pubitemid 44835126)
91. M. Hirst A two-hybrid system for transactivator bait proteins Proc. Natl. Acad. Sci. U.S.A. 98 2001 8726 8731 (Pubitemid 32678095)
92. S.W. Ki Identification of radicicol as an inhibitor of in vivo Ras/Raf interaction with the yeast two-hybrid screening system J. Antibiot. (Tokyo) 51 1998 936 944 (Pubitemid 28505288)
93. M.R. Bowlby Identification and characterization of small molecule modulators of KChIP/Kv4 function Bioorg. Med. Chem. 13 2005 6112 6119 (Pubitemid 41400132)